Explaining Adverse Events of Immune Therapy to Patients with Breast Cancer
At the 3rd annual School of Nursing Oncology (SONO) meeting, we got the chance to sit down with Madelaine Kuiper RN, MSN, and talk about what adverse events come with immune therapy for patients with breast cancer.
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC
2 Clarke Drive Cranbury, NJ 08512